Central corneal thickness and glaucoma treatment: An Italian multicenter cross-sectional study

Michele Iester, Serena Telani, Paolo Brusini, Teresa Rolle, Paolo Fogagnolo, Enrico Martini, Giovanni Milano, Daniela Paoli

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Supposedly, prostaglandin analogs (PGA) could reduce the central corneal thickness (CCT), while topical carbonic anhydrase inhibitors (TCAI) could increase CCT. The aim of the study was to evaluate clinically significant CCT effects in patients treated with PGA or TCAI. Methods: At least 50 glaucomatous patients were saved on the Italian Glaucoma Register from 16 different glaucoma centers. About 816 glaucomatous patients were found in the register; of these, 316 were recruited in this study because they were treated with PGA or TCAI. The diagnosis of glaucoma was based on visual field examination, optic nerve head analysis, intraocular pressure (IOP) measurements, and gonioscopy. Two age-matched subgroups were created: one treated with PGA and the other with TCAI. CCT, ophthalmoscopic cup/disc ratio (CDR), mean deviation (MD), pattern standard deviation (PSD), and IOP were considered for both eyes of each patient. Student t-test was used to compare the 2 subgroups. Results: The mean age of the PGA group was 66.35±12.17 years, while 65.17±12.52 years was for the TCAI group. No significant difference was found for CCT (543.75±35 μm and 544±35 μm, respectively), CDR (0.55±0.2 and 0.53±0.2, respectively), MD (-4.5±4.9 dB and -5.4±6.4 dB, respectively), PSD (4.6±3.4 and 4.6±4.9, respectively), and IOP (15.9±3.3 mmHg and 15.7±2.9 mmHg, respectively) between the 2 subgroups. A significant (P

Original languageEnglish
Pages (from-to)469-473
Number of pages5
JournalJournal of Ocular Pharmacology and Therapeutics
Volume29
Issue number5
DOIs
Publication statusPublished - 2013

Fingerprint

Carbonic Anhydrase Inhibitors
Synthetic Prostaglandins
Glaucoma
Cross-Sectional Studies
Intraocular Pressure
Gonioscopy
Therapeutics
Optic Disk
Visual Fields
Students

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology

Cite this

Central corneal thickness and glaucoma treatment : An Italian multicenter cross-sectional study. / Iester, Michele; Telani, Serena; Brusini, Paolo; Rolle, Teresa; Fogagnolo, Paolo; Martini, Enrico; Milano, Giovanni; Paoli, Daniela.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 29, No. 5, 2013, p. 469-473.

Research output: Contribution to journalArticle

Iester, Michele ; Telani, Serena ; Brusini, Paolo ; Rolle, Teresa ; Fogagnolo, Paolo ; Martini, Enrico ; Milano, Giovanni ; Paoli, Daniela. / Central corneal thickness and glaucoma treatment : An Italian multicenter cross-sectional study. In: Journal of Ocular Pharmacology and Therapeutics. 2013 ; Vol. 29, No. 5. pp. 469-473.
@article{7a6647024e4e48d18d64ba15cd2d8a1a,
title = "Central corneal thickness and glaucoma treatment: An Italian multicenter cross-sectional study",
abstract = "Purpose: Supposedly, prostaglandin analogs (PGA) could reduce the central corneal thickness (CCT), while topical carbonic anhydrase inhibitors (TCAI) could increase CCT. The aim of the study was to evaluate clinically significant CCT effects in patients treated with PGA or TCAI. Methods: At least 50 glaucomatous patients were saved on the Italian Glaucoma Register from 16 different glaucoma centers. About 816 glaucomatous patients were found in the register; of these, 316 were recruited in this study because they were treated with PGA or TCAI. The diagnosis of glaucoma was based on visual field examination, optic nerve head analysis, intraocular pressure (IOP) measurements, and gonioscopy. Two age-matched subgroups were created: one treated with PGA and the other with TCAI. CCT, ophthalmoscopic cup/disc ratio (CDR), mean deviation (MD), pattern standard deviation (PSD), and IOP were considered for both eyes of each patient. Student t-test was used to compare the 2 subgroups. Results: The mean age of the PGA group was 66.35±12.17 years, while 65.17±12.52 years was for the TCAI group. No significant difference was found for CCT (543.75±35 μm and 544±35 μm, respectively), CDR (0.55±0.2 and 0.53±0.2, respectively), MD (-4.5±4.9 dB and -5.4±6.4 dB, respectively), PSD (4.6±3.4 and 4.6±4.9, respectively), and IOP (15.9±3.3 mmHg and 15.7±2.9 mmHg, respectively) between the 2 subgroups. A significant (P",
author = "Michele Iester and Serena Telani and Paolo Brusini and Teresa Rolle and Paolo Fogagnolo and Enrico Martini and Giovanni Milano and Daniela Paoli",
year = "2013",
doi = "10.1089/jop.2012.0116",
language = "English",
volume = "29",
pages = "469--473",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Central corneal thickness and glaucoma treatment

T2 - An Italian multicenter cross-sectional study

AU - Iester, Michele

AU - Telani, Serena

AU - Brusini, Paolo

AU - Rolle, Teresa

AU - Fogagnolo, Paolo

AU - Martini, Enrico

AU - Milano, Giovanni

AU - Paoli, Daniela

PY - 2013

Y1 - 2013

N2 - Purpose: Supposedly, prostaglandin analogs (PGA) could reduce the central corneal thickness (CCT), while topical carbonic anhydrase inhibitors (TCAI) could increase CCT. The aim of the study was to evaluate clinically significant CCT effects in patients treated with PGA or TCAI. Methods: At least 50 glaucomatous patients were saved on the Italian Glaucoma Register from 16 different glaucoma centers. About 816 glaucomatous patients were found in the register; of these, 316 were recruited in this study because they were treated with PGA or TCAI. The diagnosis of glaucoma was based on visual field examination, optic nerve head analysis, intraocular pressure (IOP) measurements, and gonioscopy. Two age-matched subgroups were created: one treated with PGA and the other with TCAI. CCT, ophthalmoscopic cup/disc ratio (CDR), mean deviation (MD), pattern standard deviation (PSD), and IOP were considered for both eyes of each patient. Student t-test was used to compare the 2 subgroups. Results: The mean age of the PGA group was 66.35±12.17 years, while 65.17±12.52 years was for the TCAI group. No significant difference was found for CCT (543.75±35 μm and 544±35 μm, respectively), CDR (0.55±0.2 and 0.53±0.2, respectively), MD (-4.5±4.9 dB and -5.4±6.4 dB, respectively), PSD (4.6±3.4 and 4.6±4.9, respectively), and IOP (15.9±3.3 mmHg and 15.7±2.9 mmHg, respectively) between the 2 subgroups. A significant (P

AB - Purpose: Supposedly, prostaglandin analogs (PGA) could reduce the central corneal thickness (CCT), while topical carbonic anhydrase inhibitors (TCAI) could increase CCT. The aim of the study was to evaluate clinically significant CCT effects in patients treated with PGA or TCAI. Methods: At least 50 glaucomatous patients were saved on the Italian Glaucoma Register from 16 different glaucoma centers. About 816 glaucomatous patients were found in the register; of these, 316 were recruited in this study because they were treated with PGA or TCAI. The diagnosis of glaucoma was based on visual field examination, optic nerve head analysis, intraocular pressure (IOP) measurements, and gonioscopy. Two age-matched subgroups were created: one treated with PGA and the other with TCAI. CCT, ophthalmoscopic cup/disc ratio (CDR), mean deviation (MD), pattern standard deviation (PSD), and IOP were considered for both eyes of each patient. Student t-test was used to compare the 2 subgroups. Results: The mean age of the PGA group was 66.35±12.17 years, while 65.17±12.52 years was for the TCAI group. No significant difference was found for CCT (543.75±35 μm and 544±35 μm, respectively), CDR (0.55±0.2 and 0.53±0.2, respectively), MD (-4.5±4.9 dB and -5.4±6.4 dB, respectively), PSD (4.6±3.4 and 4.6±4.9, respectively), and IOP (15.9±3.3 mmHg and 15.7±2.9 mmHg, respectively) between the 2 subgroups. A significant (P

UR - http://www.scopus.com/inward/record.url?scp=84878564504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878564504&partnerID=8YFLogxK

U2 - 10.1089/jop.2012.0116

DO - 10.1089/jop.2012.0116

M3 - Article

C2 - 23289904

AN - SCOPUS:84878564504

VL - 29

SP - 469

EP - 473

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 5

ER -